July 18th 2025
Global acne burden in reproductive-age women has risen significantly, with greater increases expected by 2040.
3D imaging technique measures severity of atrophic acne scars
October 11th 2020There is a dire need to improve the clinical tools dermatologists use to assess the severity of acne scars. This 3D imaging technique may help, according to a recent study presented at the 2020 virtual American Society for Dermatologic Surgery (ASDS) meeting.
Case series draws attention to phenotype of acne scarring
September 10th 2020A retrospective review of patients seen in an academic dermatology clinic over a one-year period identified 20 individuals with nasal papules in association with acne, which are thought to represent scarring sequelae. The condition is underrecognized, researchers say and requires further research to better understand.
Alembic Pharmaceuticals launches adapalene gel for acne vulgaris
September 1st 2020Alembic Pharmaceuticals announces the launch of their bioequivalent and therapeutically equivalent product to Differin Gel 0.3% (Galderma), Adapalene Gel USP 0.3%, a topical retinoid for the treatment of acne vulgaris in patients 12 years and older.
Will telemedicine impact the future of acne care?
August 14th 2020Will the current practice of using telemedicine for acne care have an impact on the future of dermatology? We spoke with Julie Harper, M.D., owner and president of the Dermatology and Skin Cancer Center of Birmingham in Alabama, on the topic.
How has telemedicine impacted patient visits?
August 12th 2020Julie Harper, M.D., owner and president of the Dermatology and Skin Cancer Center of Birmingham in Alabama, discusses how she approaches treating acne via virtual visits after incorporating telemedicine into her practice due to the COVID-19 pandemic.
A ‘biomarker’ of psychiatric adverse effects with isotretinoin?
July 17th 2020While recognizing that a patient’s mental health generally improves with isotretinoin use due to improvement in acne symptoms, clinicians may consider screening for insomnia during the course of treatment, as it may be an indicator for vulnerability to side effects, researchers say.
Researchers encourage reporting on hormone therapy in acne trial demographics
July 16th 2020Many current acne clinical trials do not consider those patients already on hormone therapy, which researchers say may affect therapeutic outcomes. Authors of a recent study encourage this reporting in future studies to help clinicians better assess how the data might represent a practice population.
FDA approves new label for sarecycline
June 29th 2020Almirall announces the U.S. Food and Drug Administration has approved the updated label for their oral antibiotic sarecycline (Seysara) for treatment of acne vulgaris to help promote the appropriate use of the drug to aid in preventing antimicrobial resistance commonly warned when using antibiotics
FDA approves Aleor’s adapalene gel for acne vulgaris
June 26th 2020The U.S. Food and Drug Administration has approved the Abbreviated New Drug Application for topical retinoid adapalene gel USP, 0.3% from Alembic Pharmaceuticals and its joint venture Aleor Dermaceuticals for treatment of acne vulgaris.
Tazarotene topical for acne vulgaris launches in United States
June 25th 2020Tazarotene lotion 0.045% (Arazlo, Ortho Dermatologics) is officially launched in the U.S. following approval by the U.S. Food and Drug Administration in late 2019 for the treatment of acne vulgaris in patients 9 years and older.
Trifarotene cream proves safe, effective for acne vulgaris
May 11th 2020A recent clinical review proves trifarotene 0.005% cream is an effective and safe treatment for acne vulgaris on the face and neck in patients 9 years and older. Currently, the drug is one of four topical retinoid acne treatments available on the market.